1-4 of 4
Andrew Davies, BM PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

Myron S. Czuczman, MD, Andrew Davies, BM PhD, Kim M Linton, MBChB, MRCP, PhD, Nina Wagner-Johnston, Randy D. Gascoyne, MD, David A. Eberhard, MD PhD, Gilles Salles, MDPhD, Thomas E. Witzig, MD, Pier Luigi Zinzani, MD, PhD, George W. Wright, PhD, Louis M. Staudt, MD PhD, Jacqueline Repici, Dale Song, Oliver Manzke, MD, Ian D Lewis, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 628.
https://doi.org/10.1182/blood.V124.21.628.628
Published: 2014
Journal Articles

Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD PhD, Ian W. Flinn, MD PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD, Gilles Andre Salles, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1708.
https://doi.org/10.1182/blood.V124.21.1708.1708
Published: 2014
Journal Articles

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert Chen, MD, Andrew Davies, BM PhD, Tim Illidge, PhD, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD
Journal: Blood
Blood (2013) 122 (21): 4386.
https://doi.org/10.1182/blood.V122.21.4386.4386
Published: 2013
Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay Gopal, MD, Brad S. Kahl, MD, Sven De Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Kristie A. Blum, MD, Wojciech J. Jurczak, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, PhD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Daniel Li, PhD, Roger Dansey, MD, Wayne R. Godfrey, MD, Gilles A. Salles, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 85.
https://doi.org/10.1182/blood.V122.21.85.85
Published: 2013